Topic: personalized medicine
Voluntis received an FDA clearance for a mobile app that helps patients manage their symptoms across all different types of cancer.
Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.
Notable Labs is adding $40 million to its reserves as it scales up its capabilities with plans to take its platform worldwide.
Health Catalyst and MedRhythms aim to develop a digital therapeutic incorporating AI-generated music and sensor data to help stroke survivors walk.
ArcherDX has closed on a $60 million financing round to support its companion diagnostic program spanning solid and blood tumors.
Some microRNAs could serve as prognostic markers of Crohn's and open the possibility of developing personalized therapies.
Cancer blood test company Epic Sciences raised $52 million to move its treatment-guiding liquid biopsies toward regulatory approval.
Researchers at Mount Sinai say they’ve identified two biomarkers that may improve the treatment of an aggressive subtype of bladder cancer.
The fund will invest in companies that tap into AI and the internet of things to deliver devices tailored to the biology and lifestyle of individuals.
Scientists at the University of Cambridge have shown in animal models that reprogramming patients’ own skin cells may be an effective way to treat MS.